Latest Partnerships News

Aerometrex reported a slight dip in overall revenue for FY25 but achieved record growth in its MetroMap subscription business, driving a 19.8% rise in EBITDA. Strategic shifts and new leadership position the company for a leaner, more profitable future.

Harvey Norman Holdings Limited reported strong FY25 financial results, driven by growth in franchisee sales, property portfolio appreciation, and digital investments. The company’s integrated retail, franchise, property, and digital system across multiple countries underpins its sustained shareholder returns.

Murray Cod Australia Limited has reported a remarkable turnaround with a $8.56 million profit for FY25, driven by expanded production capacity and growing export markets. The company’s strategic focus on domestic strength and sustainable growth underpins its rising global profile.

Nutritional Growth Solutions reported a 30% drop in revenue to US$867k for H1 FY25 but narrowed its loss to US$1.2 million, driven by cost discipline and new retail partnerships including Walmart and CVS.

Cluey Ltd reported a significantly reduced loss for FY25 alongside an 11% increase in new students and achieved positive operating cash flow in Q4, signaling progress in its path to profitability.

K2 Asset Management Holdings Ltd has reported a strong financial year ending June 2025, with revenues up 17% and a return to profitability, alongside a fully franked dividend declaration.

Australian Dairy Nutritionals Group (ASX, AHF) reported a 14% revenue increase to $7.17 million for FY25, driven by a nearly fourfold surge in its infant formula segment, while reducing its net loss by 29%. The company remains debt-free and is expanding its footprint in China and Vietnam.

Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.

LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.

Metal Powder Works Limited reported a 15% revenue decline and a 224% surge in net loss for FY2025, driven by acquisition costs and a pivot towards long-term contracts.

LTR Pharma Limited (ASX, LTP) reported significant progress in FY25, advancing its novel intranasal treatments for erectile dysfunction and expanding its commercial footprint in Australia and the US. The company secured key partnerships and capital raises, positioning itself for regulatory milestones and global market entry.

Gratifii Limited has reported a robust FY25 with revenue and transaction values more than doubling, driven by key acquisitions and new product launches. The company is poised for further growth in FY26 with platform upgrades and expanding client partnerships.